Louise S. Dalbøge’s Post

Are you attending #Tides2024 in Boston this week? 💡 We value your insights and invite you to join us at booth #419. James McAllister, Phil Shymanski and Brenda Karim are ready to explain how our PurePep solutions can elevate your peptide projects together. 💊Tow major trends transform the landscape of peptide therapeutics dramatically ⭐ Chemical or display screening platforms become state-of-the-art for target-based drug development, resulting in a significantly enriched preclinical pipeline. ⭐ The success of GLP-1 analogs for weight loss and obesity treatment is moon-shooting the pharmaceutical relevance of peptides, causing a shortage of external synthesis capacity. 👉🏽 The performance of novel drug development projects hinges on a seamless transition from screening to the clinics. A critical component is the synthetic in-house capability to rapidly scale up and improve peptide quality in parallel, along with the ability to adopt complex chemistry to advance the stability and efficacy of your lead compounds. ⏳ The clock is ticking. It's crucial to equip ourselves with the right manufacturing tools to stay ahead of the curve in peptide therapeutics. ' See you at booth #419.

🔬 Exciting News in Clinical Research! 🔬 🌟 CytoDyn’s Legal Battle Against Amarex Clinical Research, LLC, an NSF company Ends with $12 Million Settlement 🌟 In a recent development, CytoDyn, a late-stage biotechnology company, has successfully resolved its legal dispute with former contract research organization (CRO) Amarex Clinical Services. The settlement amounts to a substantial $12 million. 🔍 Background: CytoDyn focuses on developing innovative treatments for various therapeutic indications using Leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptor. This receptor plays a central role in modulating immune cell trafficking to sites of inflammation. 🚀 Implications: The resolution of this legal battle allows CytoDyn to shift its focus back to advancing clinical trials and bringing potentially life-changing therapies to patients. It’s a significant win for both companies and the broader medical community. 📈 Stay Tuned: Keep an eye on CytoDyn’s progress as they continue their groundbreaking research. Exciting times lie ahead! #healthcare #biotech #lifescience #Contractresearch #pharmaceuticals #pharma #CRO #Clinical

Vancouver Biotech Inks Partnership with Novo Nordisk Worth Up to $800 Million NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with Danish pharmaceutical company Novo Nordisk that could be worth up to $800 million. The two companies will collaborate on the development of gene-editing therapies for certain rare genetic diseases. Under terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to $600 million in cash and milestone payments. NanoVation may also be eligible for tiered royalties on future product sales. NanoVation Therapeutics developed technology called long-circulating lipid nanoparticle (lcLNP) that overcomes certain barriers to nucleic acid delivery. https://lnkd.in/ghH4eJ35 #aspenalert #biotech #bioprocess

Ready for some groundbreaking insights? Join us at the Oligonucleotide Therapeutics and Delivery conference in London on September 9-10 to hear the inside scoop on Cardior’s $1.1 billion acquisition by Novo Nordisk! Thomas Thum, the visionary Founder, Chief Scientific Officer, and Chief Medical Officer of Cardior Pharmaceuticals GmbH, will take the stage to discuss ‘Non-Coding RNA-based Therapeutics at the Pulse of Heart Disease’. Here's what you'll learn: - The latest on the ongoing phase 2 trial in heart failure patients: Discover how the oligonucleotide R&D landscape is revolutionizing heart failure treatments. - Cardior Pharmaceuticals/pharma company interaction: What this means for strengthened RNA-based pipelines for chronic populations - Delving into further drug discovery pipelines in heart failure subgroups, where is research and funding still needed? This is your chance to gain exclusive insight from a pioneer in the field. Don’t miss out! 🎟️ Secure your ticket now!➡https://ow.ly/t4Ty50SyNNA #SAEMGPharma #Pharma #OligoTherapeutics #OligoResearch #NucleicAcidTherapeutics #GeneTherapy #RNAi #Biotechnology #PrecisionMedicine #PharmaInnovation #TherapeuticDevelopment #Biopharma #GeneticMedicine #MolecularBiology #OligoTx

Two must-attend sessions at the Oligonucleotide Therapeutics Xchange - Maryland 2024, 30 October, that you won't want to miss! Secure your free pass: https://lnkd.in/eWms8KbQ 🎯 Sponsor-led Roundtable Discussion: "Manufacturing n-of-1 Batches - Helping 1 Patient at a Time?" ⏰ 11:25 AM - 12:25 PM Join us for a sponsor-led roundtable discussion where we'll delve into the intricacies of manufacturing n-of-1 batches—a groundbreaking approach that could revolutionize personalized medicine, one patient at a time. This is a unique opportunity to engage with industry experts, exchange ideas, and explore innovative strategies in oligonucleotide manufacturing. 🎤 Poster Presentation: "Thiophosphoramidate Morpholino Oligonucleotides (TMOs): A Novel Class of PMOs Compatible With Conventional Automated Oligonucleotide Synthesis" ⏰ 3:15 PM - 3:45 PM Presented by Jeremy Little, Director of Custom Oligonucleotides at ChemGenes this session will showcase the latest advancements in TMOs—a novel class of PMOs that are set to enhance oligonucleotide synthesis. With over a decade of experience in nucleic acid drug discovery and oligonucleotide manufacturing, Jeremy brings unparalleled expertise to the table. Whether you're involved in biotech, pharma, or are just passionate about the future of oligonucleotide therapeutics, these sessions are invaluable. 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #LifeSciences #PrecisionMedicine #NucleicAcids #Pharmaceuticals #MedicalInnovation #Healthcare #Biotechnology #DrugDevelopment #MolecularBiology #ScientificResearch #GeneTherapy #OligonucleotideSynthesis #Biopharma #FutureOfMedicine #BiotechIndustry #InnovationInHealthcare #PharmaResearch #MedicinalChemistry #ClinicalResearch #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

We are excited to announce that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the clinical study of its TEAD inhibitor BGC515 for the treatment of cancers harboring genetic mutations in the hippo signaling pathway.   "We are pleased to announce the FDA acceptance of our IND application for BGC515 and look forward to initiating this Phase I clinical study to evaluate the safety and efficacy profile of BGC515 in patients with advanced solid tumors," stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences. "Discovered through our unique chemoproteomic platform, IMTAC™, the TEAD inhibitor BGC515 represents a significant breakthrough. The FDA's endorsement of this IND not only validates our innovative platform but also highlights a critical step forward in our mission to develop pioneering treatments for cancer patients. Learn more at https://lnkd.in/gzU2BnzF #BridGeneBiosciences #FDAApproval #BGC515 #CancerResearch #Innovation #HealthcareInnovation #ClinicalTrials #Biotech #Pharmaceuticals #Oncology #DrugDiscovery #Biotechnology #MedicalResearch #LifeSciences #TEADInhibitor #PrecisionMedicine #TherapeuticInnovation

Webinar alert for peptide scientists and drug developers 🚨🚨🚨 This is your can't-miss opportunity to learn how to transition from screening to lead optimization in peptide drug development. Join us for an insightful webinar with featured speaker Will Blackwell, Director of Chemistry at Aktis Oncology, on the crucial role of peptide synthesis in modern drug development. Learn how to optimize peptide synthesis and application to navigate bottlenecks and enhance the drug development cycle. ⭐️How to design a robust synthesis to benefit the #SAR process ⭐️Which information from various disciplines in the SAR design ensures success ⭐️The criticality of chemical flexibility to allow for creative design and thorough investigation of SAR ⭐️About teamwork and its meaning during a drug discovery program Date: July 30, 2024 Time:  10am EDT / 3pm BST / 4pm CEST Register now: https://lnkd.in/gN_zrZ38 #peptides #purepep #synthesis #purification

For an insightful webinar about organoids and how ACROBiosystems' organoid solutions revolutionize the pharmaceutical landscape, feel free to go register 👇

🚀 Exciting News in Pharma! 🌟 In 2023, the FDA unleashed a wave of innovation with a record-breaking 55 new drug approvals, marking a remarkable rebound after a challenging 2022. 🎉 🏆 Pfizer stole the spotlight, securing 7 FDA nods, more than double the closest competitor! 🌐 This historic achievement follows their groundbreaking $100 billion annual revenue in 2022. 🔬 The diverse portfolio includes treatments for multiple myeloma, growth failure, alopecia, RSV, and COVID-19. Notably, Pfizer's success was fueled by strategic acquisitions and its COVID vaccine success. 🔥 Martin Mackay, Ph.D., predicts a golden age of drug discovery, citing advancements in cell therapy, gene therapy, RNA, and more. 🌍 This year's approvals showcase a wide variety of modalities, with small molecules leading the way. 👏 Kudos to the FDA for supporting innovation, and congrats to all the companies making a difference in healthcare! 🔗 https://lnkd.in/eBKF3fjX #PharmaInnovation #FDAApprovals #Pfizer #DrugDiscovery #HealthcareAdvancements #Biopharma #MedicalBreakthroughs #Innovation2023 #MedicalResearch #FDA #Biologics #MedicalAdvancements #GeneTherapies #RSVVaccines #AlzheimersTreatment #LeqembiApproval #MedicalScience